Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R)

被引:57
作者
Ling, MT
Wang, XH
Lee, DT
Tam, PC
Tsao, SW
Wong, YC
机构
[1] Univ Hong Kong, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Fac Med, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1093/carcin/bgh047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The failure of prostate cancer treatment is largely due to the development of androgen independence, since the androgen depletion therapy remains the front-line option for this cancer. Previously, we reported that over-expression of the helix-loop-helix protein Id-1 was associated with progression of prostate cancer and ectopic expression of Id-1 induced serum-independent proliferation in prostate cancer cells. In the present study, we investigated if exogenous Id-1 expression in the androgen sensitive LNCaP cells had any effect on androgen-dependent cell growth and studied the molecular mechanisms involved. Using stable Id-1 transfectants, we found that expression of Id-1 was able to reduce androgen-stimulated growth and S phase fraction of the cell cycle in LNCaP cells, indicating that Id-1 may be involved in the development of androgen independence in these cells. The Id-1-induced androgen-independent prostate cancer cell growth was correlated with up-regulation of EGF-R (epidermal growth factor-receptor) and PSA (prostate specific antigen) expression, as confirmed by western blotting analysis and luciferase assays. In contrast, down-regulation of Id-1 in androgen-independent DU145 cells by its antisense oligonucleotides resulted in suppression of EGF-R expression at both transcriptional and protein levels. In addition, the results from immunohistochemistry study showed that Id-1 expression was significantly elevated in hormone refractory prostate cancer tissues when compared with the hormone-dependent tumours. Our results suggest that up-regulation of Id-1 in prostate cancer cells may be one of the mechanisms responsible for developing androgen independence and this process may be regulated through induction of EGF-R expression. Inactivation of Id-1 may provide a potential therapeutic strategy leading to inhibition of androgen-independent prostate cancer cell growth.
引用
收藏
页码:517 / 525
页数:9
相关论文
共 50 条
[41]   EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) AND TRANSFORMING GROWTH-FACTOR-ALPHA (TGFA) EXPRESSION IN DIFFERENT ENDOMETRIAL CANCERS [J].
JASONNI, VM ;
AMADORI, A ;
SANTINI, D ;
CECCARELLI, C ;
NALDI, S ;
FLAMIGNI, C .
ANTICANCER RESEARCH, 1995, 15 (04) :1327-1332
[42]   Epidermal growth factor receptor (EGF-r) tyrosine kinase activity, tissue EGF-r and EGF concentrations in human endometrial adenocarcinoma. [J].
Miturski, R ;
Tomaszewski, J ;
Kotarski, J .
FASEB JOURNAL, 1996, 10 (06) :317-317
[43]   An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells [J].
Shi, Xu-Bao ;
Xue, Lingru ;
Yang, Joy ;
Ma, Ai-Hong ;
Zhao, Jianjun ;
Xu, Ma ;
Tepper, Clifford G. ;
Evans, Christopher P. ;
Kung, Hsing-Jien ;
White, Ralph W. deVere .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (50) :19983-19988
[44]   The effect of combination growth factor receptor and mTOR inhibitors in androgen-independent prostate cancer cell tines. [J].
Bubley, GJ ;
Masiello, D ;
McKnight, N ;
Smith, B ;
Mohi, G ;
Neel, B ;
Balk, S .
CLINICAL CANCER RESEARCH, 2003, 9 (16) :6179S-6180S
[45]   IS THERE A ROLE FOR EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IN THE PROGRESSION OF RENAL CYSTS [J].
LAKSHMANAN, J ;
ZEEH, J ;
SOTTILI, M ;
HOFFMANN, P ;
REINSHAGEN, M ;
PATEL, A ;
EYSSELEIN, V .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03) :700-700
[46]   EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IS NOT EXPRESSED IN CPK CYSTIC KIDNEYS [J].
SOTTILI, M ;
ZEEH, JM ;
HOFFMANN, P ;
EYSSELEIN, VE ;
LAKSHMANAN, J .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03) :636-636
[47]   Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, ΔEGF-R, and de2-7 EGF-R) [J].
Purev, E ;
Cai, DW ;
Miller, E ;
Swoboda, R ;
Klein-Szanto, A ;
Marincola, FM ;
Mick, R ;
Otvos, L ;
Wunner, W ;
Birebent, B ;
Somasundaram, R ;
Wikstrand, CJ ;
Bigner, D ;
DeMichele, A ;
Acs, G ;
Berlin, JA ;
Herlyn, D .
JOURNAL OF IMMUNOLOGY, 2004, 173 (10) :6472-6480
[48]   Androgen receptor silencing inhibits growth of androgen-independent LNCaP prostate cancer variants [J].
Mack, Philip C. ;
Burich, Rebekah A. ;
White, Ralph W. Devere .
CANCER RESEARCH, 2006, 66 (08)
[49]   Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo [J].
Ishii, Kenichiro ;
Imamura, Tetsuya ;
Iguchi, Kazuhiro ;
Arase, Shijeki ;
Yoshio, Yuko ;
Arima, Kiminobu ;
Hirano, Kazuyuki ;
Sugimura, Yoshiki .
ENDOCRINE-RELATED CANCER, 2009, 16 (02) :415-428
[50]   Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines [J].
S. Hoffmann ;
A. Burchert ;
A. Wunderlich ;
Y. Wang ;
S. Lingelbach ;
L. C. Hofbauer ;
M. Rothmund ;
A. Zielke .
Endocrine, 2007, 31 :105-113